| Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767) |
|---|
| 02/05/2004 | WO2004011611A2 Taci antibodies and uses thereof |
| 02/05/2004 | WO2004011470A1 Furoisoquinoline derivative and use thereof |
| 02/05/2004 | WO2004011465A1 Kinase inhibitors |
| 02/05/2004 | WO2004011444A2 Novel method for preparing styryl pyrazole, isoxazole and isothiazole derivatives |
| 02/05/2004 | WO2004011443A1 Pyrimidyl sulphone amide derivatives as chemokine receptor modulators |
| 02/05/2004 | WO2004011418A1 3,4-di-substituted cyclobutene-1, 2-diones as cxc-chemokine receptor ligands |
| 02/05/2004 | WO2004011416A1 CRYSTALLINE β2 ADRENERGIC RECEPTOR AGONIST |
| 02/05/2004 | WO2004011410A1 Chemical compounds |
| 02/05/2004 | WO2004011402A2 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |
| 02/05/2004 | WO2004011069A1 Medicament dispenser |
| 02/05/2004 | WO2004011068A1 Medicament dispenser |
| 02/05/2004 | WO2004011067A1 Medicament dispenser |
| 02/05/2004 | WO2004011028A1 Use of digoxin immune fab for the regulation of sodium/potassium atpase activity in preeclamptic and eclamptic patients |
| 02/05/2004 | WO2004011017A1 Nasal irrigation solutions and methods of using same |
| 02/05/2004 | WO2004011001A1 Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
| 02/05/2004 | WO2004010995A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis |
| 02/05/2004 | WO2004010974A2 Gelatin capsule exhibiting reduced cross-linking |
| 02/05/2004 | WO2004010973A2 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| 02/05/2004 | WO2004010972A2 Pellicle-resistant gelatin capsule |
| 02/05/2004 | WO2004010969A1 Chinese herb medicine composition in the form of jelly |
| 02/05/2004 | WO2004010945A2 Cyclooxygenase- 2 selective inhibitors, compositions and methods of use |
| 02/05/2004 | WO2004010935A2 Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies |
| 02/05/2004 | WO2003084938A3 Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases |
| 02/05/2004 | WO2003084560A3 Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis |
| 02/05/2004 | WO2003082244A3 Hfa-suspension formulation of an anhydrate |
| 02/05/2004 | WO2003075857A3 Amino-methyl substituted tetracycline compounds |
| 02/05/2004 | WO2003074654A3 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| 02/05/2004 | WO2003066091A3 Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations employing tirc7 |
| 02/05/2004 | WO2003066067A3 Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases |
| 02/05/2004 | US20040024224 Synthesis of 2-alkyl amino acids |
| 02/05/2004 | US20040024218 Novel compounds |
| 02/05/2004 | US20040024217 Synthesis of piperidine and piperazine compounds as CCR5 antagonists |
| 02/05/2004 | US20040024208 Cyclic protein tyrosine kinase inhibitors |
| 02/05/2004 | US20040024197 Synthetic oligo- and polysaccharides exhibiting at least one covalent bond with biotin or a biotin derivative and having the anticoagulant and antithrombotic pharmacological activities of heparin |
| 02/05/2004 | US20040024066 E.g., N-(2-(Benzo(b)thiophen-5-ylmethanesulfonyl)-1-(3,4-dichloro- phenyl)- ethyl)-N-hydroxyformamide; gene expression inhibitors of s-CD23; autoimmune disease; antiallergens; matrix metalloprotease enzyme inhibitors |
| 02/05/2004 | US20040024060 Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 02/05/2004 | US20040024030 Such as 4-chloro-5-(2-phenyl-thiazol-5-yl)-2H-pyrazole-3-carboxylic acid ethyl amide; for inhibiting topoisomerases; treating bacterial infections in mammals |
| 02/05/2004 | US20040024029 Thiazole and oxazole derivatives |
| 02/05/2004 | US20040023998 2-(5-amino-6-oxo-2-phenyl-1,6-dihydro-1-pyrimidyl)-N-(1-(2-(5-t -butyl-1,3,4-oxadiazolyl)carbonyl)-2-(R,S)-methylpropyl) acetamide; elastase inhibitors |
| 02/05/2004 | US20040023995 Pyridopyrimidine compounds and their uses |
| 02/05/2004 | US20040023992 Antiinflammatory agents |
| 02/05/2004 | US20040023990 Use of pyrazolo[4,3-d]pyrimidines |
| 02/05/2004 | US20040023963 Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| 02/05/2004 | US20040023950 N-heterocyclic derivatives as NOS inhibitors |
| 02/05/2004 | US20040023945 Cyclic amp-specific phosphodiesterase inhibitors |
| 02/05/2004 | US20040023941 Modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and |
| 02/05/2004 | US20040023900 Derivatives of monosaccharides as cell adhesion inhibitors |
| 02/05/2004 | US20040023898 Single dose azithromycin |
| 02/05/2004 | US20040023883 IGF-I and insulin variants are provided that selectively bind to IGFBP-1 or IGFBP-3. These agonist variants are useful, for example, to improve the half-lives of IGF-I and insulin, respectively. |
| 02/05/2004 | US20040023854 Adiponectin and uses thereof |
| 02/05/2004 | US20040022879 Platelet Activating Factor Inhibitor and an antioxidant which interferes with the arachidonic acid cascade and also has antioxidant activity; especially useful for treating asthma in children. |
| 02/05/2004 | US20040022870 Immunogenic TLP composition |
| 02/05/2004 | US20040022851 Sustained release of guaifenesin combination drugs |
| 02/05/2004 | US20040022801 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 02/05/2004 | US20040022793 Vaccine comprising active agent immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide |
| 02/05/2004 | US20040022785 Expression of herstatin, an alternative HER-2/neu product, in cells that express either p185HER-2 or the EGF receptor inhibits receptor activity and cell growth |
| 02/05/2004 | US20040022783 Binding agents to CD23 |
| 02/05/2004 | US20040022762 Use of il-8 protein modulators in the treatment of viral infections |
| 02/05/2004 | DE10231370A1 Neue Thiophenglycosidderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung Thiophenglycosidderivate new, processes for their preparation, pharmaceutical compositions containing them and their use |
| 02/05/2004 | CA2727782A1 Canine respiratory coronavirus (crcv) spike protein, polymerase and hemagglutinin/esterase |
| 02/05/2004 | CA2494668A1 Chemical compounds |
| 02/05/2004 | CA2494485A1 Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies |
| 02/05/2004 | CA2494358A1 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| 02/05/2004 | CA2494069A1 Pellicle-resistant gelatin capsule |
| 02/05/2004 | CA2493980A1 Gelatin capsule exhibiting reduced cross-linking |
| 02/05/2004 | CA2493751A1 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |
| 02/05/2004 | CA2493156A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 02/05/2004 | CA2493128A1 Crystalline .beta.2 adrenergic receptor agonist |
| 02/05/2004 | CA2493078A1 Medicament dispenser |
| 02/05/2004 | CA2492858A1 Use of digoxin immune fab for the regulation of sodium/potassium atpase activity in preeclamptic and eclamptic patients |
| 02/05/2004 | CA2492490A1 Chinese herbal medical composition in the form of jelly |
| 02/05/2004 | CA2492447A1 Taci antibodies and uses thereof |
| 02/05/2004 | CA2492333A1 Canine respiratory coronavirus (crcv) spike protein, polymerase and hemagglutinin/esterase |
| 02/04/2004 | EP1386933A1 Cytokine antagonists and agonists |
| 02/04/2004 | EP1386923A1 Novel adenine derivatives |
| 02/04/2004 | EP1386912A1 Cyclic amidine derivative |
| 02/04/2004 | EP1386908A1 Amine derivative with potassium channel regulatory function, its preparation and use |
| 02/04/2004 | EP1386155A2 Therapeutic and diagnostic uses of antibody specificity profiles |
| 02/04/2004 | EP1385977A2 Secreted proteins |
| 02/04/2004 | EP1385934A2 Pufa polyketide synthase systems and uses thereof |
| 02/04/2004 | EP1385883A2 Transmembrane proteins |
| 02/04/2004 | EP1385878A2 Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds |
| 02/04/2004 | EP1385861A2 Compositions and methods relating to lung specific genes and proteins |
| 02/04/2004 | EP1385854A1 Thiazolopyrimidines and their use as modulators of chemokine receptor activity |
| 02/04/2004 | EP1385848A2 Phtalazinones derivatives useful as pde4/7 inhibitors |
| 02/04/2004 | EP1385845A1 N-aroyl cyclic amines |
| 02/04/2004 | EP1385843A1 Arylindenopyridines with pde inhibiting activity |
| 02/04/2004 | EP1385841A1 Sulfonamides |
| 02/04/2004 | EP1385840A1 Sulfonamides |
| 02/04/2004 | EP1385839A1 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists |
| 02/04/2004 | EP1385838A1 Piperazino-derivatives and their use as pde4 inhibitor |
| 02/04/2004 | EP1385836A2 Aromatic sulfone hydroxamates and their use as protease inhibitors |
| 02/04/2004 | EP1385830A1 Sulfonamides |
| 02/04/2004 | EP1385822A1 Aminopyrrolidine sulfonamides as serine protease inhibitors |
| 02/04/2004 | EP1385550A2 Therapeutic method for inducing tolerance |
| 02/04/2004 | EP1385535A2 Modified fvii in treatment of ards |
| 02/04/2004 | EP1385524A1 Pyrazolopyrimidines as therapeutic agents |
| 02/04/2004 | EP1385519A2 Compounds for treating inflammatory diseases |
| 02/04/2004 | EP1385518A1 Benzimidazolone compounds |
| 02/04/2004 | EP1385514A1 Spiroindene and spiroindane compounds |